214 related articles for article (PubMed ID: 17459937)
1. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus.
Faber M; Faber ML; Li J; Preuss MA; Schnell MJ; Dietzschold B
J Virol; 2007 Jul; 81(13):7041-7. PubMed ID: 17459937
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity.
Faber M; Faber ML; Papaneri A; Bette M; Weihe E; Dietzschold B; Schnell MJ
J Virol; 2005 Nov; 79(22):14141-8. PubMed ID: 16254349
[TBL] [Abstract][Full Text] [Related]
3. Generation of a novel live rabies vaccine strain with a high level of safety by introducing attenuating mutations in the nucleoprotein and glycoprotein.
Nakagawa K; Nakagawa K; Omatsu T; Katayama Y; Oba M; Mitake H; Okada K; Yamaoka S; Takashima Y; Masatani T; Okadera K; Ito N; Mizutani T; Sugiyama M
Vaccine; 2017 Oct; 35(42):5622-5628. PubMed ID: 28882441
[TBL] [Abstract][Full Text] [Related]
4. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife.
Dietzschold ML; Faber M; Mattis JA; Pak KY; Schnell MJ; Dietzschold B
Vaccine; 2004 Dec; 23(4):518-24. PubMed ID: 15530701
[TBL] [Abstract][Full Text] [Related]
5. Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus.
Yamada K; Park CH; Noguchi K; Kojima D; Kubo T; Komiya N; Matsumoto T; Mitui MT; Ahmed K; Morimoto K; Inoue S; Nishizono A
Virus Res; 2012 Apr; 165(1):34-45. PubMed ID: 22248643
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation.
Tao L; Ge J; Wang X; Zhai H; Hua T; Zhao B; Kong D; Yang C; Chen H; Bu Z
J Virol; 2010 Sep; 84(17):8926-36. PubMed ID: 20538851
[TBL] [Abstract][Full Text] [Related]
7. Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
Yamada K; Noguchi K; Nishizono A
Virus Res; 2014 Jan; 179():169-76. PubMed ID: 24177272
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife.
Faber M; Dietzschold B; Li J
Zoonoses Public Health; 2009 Aug; 56(6-7):262-9. PubMed ID: 19486317
[TBL] [Abstract][Full Text] [Related]
9. Generation of a live rabies vaccine strain attenuated by multiple mutations and evaluation of its safety and efficacy.
Nakagawa K; Ito N; Masatani T; Abe M; Yamaoka S; Ito Y; Okadera K; Sugiyama M
Vaccine; 2012 May; 30(24):3610-7. PubMed ID: 22464967
[TBL] [Abstract][Full Text] [Related]
10. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV.
Wirblich C; Schnell MJ
J Virol; 2011 Jan; 85(2):697-704. PubMed ID: 21068252
[TBL] [Abstract][Full Text] [Related]
11. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein.
Mebatsion T
J Virol; 2001 Dec; 75(23):11496-502. PubMed ID: 11689631
[TBL] [Abstract][Full Text] [Related]
12. A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein.
Takayama-Ito M; Inoue K; Shoji Y; Inoue S; Iijima T; Sakai T; Kurane I; Morimoto K
Virus Res; 2006 Aug; 119(2):208-15. PubMed ID: 16473429
[TBL] [Abstract][Full Text] [Related]
13. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.
Cenna J; Tan GS; Papaneri AB; Dietzschold B; Schnell MJ; McGettigan JP
Vaccine; 2008 Nov; 26(50):6405-14. PubMed ID: 18804506
[TBL] [Abstract][Full Text] [Related]
14. Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
Ito N; Okamoto T; Sasaki M; Miyamoto S; Takahashi T; Izumi F; Inukai M; Jarusombuti S; Okada K; Nakagawa K; Fujii Y; Nishiyama S; Masatani T; Sawa H; Sugiyama M
Vaccine; 2021 Jun; 39(28):3777-3784. PubMed ID: 34092430
[TBL] [Abstract][Full Text] [Related]
15. Genetic stability (in vivo) of the attenuated oral rabies virus vaccine SAD B19.
Beckert A; Geue L; Vos A; Neubert A; Freuling C; Müller T
Microbiol Immunol; 2009 Jan; 53(1):16-21. PubMed ID: 19161553
[TBL] [Abstract][Full Text] [Related]
16. A unique substitution at position 333 on the glycoprotein of rabies virus street strains isolated from non-hematophagous bats in Brazil.
Sato G; Kobayashi Y; Motizuki N; Hirano S; Itou T; Cunha EM; Ito FH; Sakai T
Virus Genes; 2009 Feb; 38(1):74-9. PubMed ID: 18941881
[TBL] [Abstract][Full Text] [Related]
17. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.
Foley HD; McGettigan JP; Siler CA; Dietzschold B; Schnell MJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14680-5. PubMed ID: 11114165
[TBL] [Abstract][Full Text] [Related]
18. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach.
Morimoto K; Foley HD; McGettigan JP; Schnell MJ; Dietzschold B
J Neurovirol; 2000 Oct; 6(5):373-81. PubMed ID: 11031690
[TBL] [Abstract][Full Text] [Related]
19. [A new principle in the selection of vaccinal rabies virus based on quantitation of the expression of G protein, a major immunogen of rabies virus].
Gribencha SV; Losich MA; Gribencha LF; Nepoklonova IV
Vopr Virusol; 2012; 57(3):44-7. PubMed ID: 22905428
[TBL] [Abstract][Full Text] [Related]
20. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system.
Wang ZW; Sarmento L; Wang Y; Li XQ; Dhingra V; Tseggai T; Jiang B; Fu ZF
J Virol; 2005 Oct; 79(19):12554-65. PubMed ID: 16160183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
